Stock Track | Haixi Pharma Soars 5.06% Intraday on Broker Buy Rating and Strong Drug Pipeline Progress

Stock Track04-28

Haixi Pharma's stock surged 5.06% during intraday trading on Tuesday, continuing its strong performance this year.

The price movement follows Shenwan Hongyuan's initiation of coverage on the company with a Buy rating and a target price of HK$298.28. The broker highlighted Haixi Pharma's generic drug business, which has achieved five consecutive years of profitability, and its strong fiscal year 2025 results with revenue reaching RMB 582 million (up 25% year-on-year) and net profit hitting RMB 177 million (a 30% increase).

Additionally, the company's aggressive push into innovative drug research and development is providing further catalysts. Lead candidate C019199 is poised to enter Phase III clinical trials for osteosarcoma in the first half of the year, while novel oral drug HXP056 for fundus diseases has demonstrated favorable Phase I safety and tolerability data in patients with wet age-related macular degeneration, showing preliminary improvements in retinal morphology and function.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141705590?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141705590","market":"sg","top_or_hot":-1,"title":"Stock Track | Haixi Pharma Soars 5.06% Intraday on Broker Buy Rating and Strong Drug Pipeline Progress","media":"Stock Track","content":"<p>Haixi Pharma's stock surged 5.06% during intraday trading on Tuesday, continuing its strong performance this year.</p><p>The price movement follows Shenwan Hongyuan's initiation of coverage on the company with a Buy rating and a target price of HK$298.28. The broker highlighted Haixi Pharma's generic drug business, which has achieved five consecutive years of profitability, and its strong fiscal year 2025 results with revenue reaching RMB 582 million (up 25% year-on-year) and net profit hitting RMB 177 million (a 30% increase).</p><p>Additionally, the company's aggressive push into innovative drug research and development is providing further catalysts. Lead candidate C019199 is poised to enter Phase III clinical trials for osteosarcoma in the first half of the year, while novel oral drug HXP056 for fundus diseases has demonstrated favorable Phase I safety and tolerability data in patients with wet age-related macular degeneration, showing preliminary improvements in retinal morphology and function.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Haixi Pharma Soars 5.06% Intraday on Broker Buy Rating and Strong Drug Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Haixi Pharma Soars 5.06% Intraday on Broker Buy Rating and Strong Drug Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-28 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Haixi Pharma's stock surged 5.06% during intraday trading on Tuesday, continuing its strong performance this year.</p><p>The price movement follows Shenwan Hongyuan's initiation of coverage on the company with a Buy rating and a target price of HK$298.28. The broker highlighted Haixi Pharma's generic drug business, which has achieved five consecutive years of profitability, and its strong fiscal year 2025 results with revenue reaching RMB 582 million (up 25% year-on-year) and net profit hitting RMB 177 million (a 30% increase).</p><p>Additionally, the company's aggressive push into innovative drug research and development is providing further catalysts. Lead candidate C019199 is poised to enter Phase III clinical trials for osteosarcoma in the first half of the year, while novel oral drug HXP056 for fundus diseases has demonstrated favorable Phase I safety and tolerability data in patients with wet age-related macular degeneration, showing preliminary improvements in retinal morphology and function.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1141705590","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141705590","pubTimestamp":1777340905,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Haixi Pharma's stock surged 5.06% during intraday trading on Tuesday, continuing its strong performance this year.The price movement follows Shenwan Hongyuan's initiation of coverage on the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"个股赛道|海西药业盘中大涨5.06%获券商买入评级药物管线进展强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Haixi Pharma's stock surged 5.06% during intraday trading on Tuesday, continuing its strong performance this year.The price movement follows Shenwan Hongyuan's initiation of coverage on the company with a Buy rating and a target price of HK$298.28. The broker highlighted Haixi Pharma's generic drug business, which has achieved five consecutive years of profitability, and its strong fiscal year 2025 results with revenue reaching RMB 582 million (up 25% year-on-year) and net profit hitting RMB 177 million (a 30% increase).Additionally, the company's aggressive push into innovative drug research and development is providing further catalysts. Lead candidate C019199 is poised to enter Phase III clinical trials for osteosarcoma in the first half of the year, while novel oral drug HXP056 for fundus diseases has demonstrated favorable Phase I safety and tolerability data in patients with wet age-related macular degeneration, showing preliminary improvements in retinal morphology and function.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141705590","isCrawlerRequest":true}